NEW YORK – Amgen and Adaptive Biotechnologies said on Thursday that they are collaborating to discover and develop human antibody-based treatments for COVID-19.
The companies have signed a memorandum of understanding and plan to execute a collaboration and license agreement, the terms of which will not be disclosed.